Newborn screening

Pathology

Volumn 40, Issue 2, 2008, Pages 104-115

  Wilcken, Bridget ^a,b   Wiley, Veronica ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Congenital hypothyroidism; Cystic fibrosis; Dried blood spot; Medium chain acyl CoA dehydrogenase deficiency; Newborn screening; Tandem mass spectrometry

Indexed keywords

BIOTINIDASE DEFICIENCY; CONGENITAL ADRENAL HYPERPLASIA; CONGENITAL HYPOTHYROIDISM; COST BENEFIT ANALYSIS; CYSTIC FIBROSIS; DNA DETERMINATION; DNA EXTRACTION; ENZYME DEFICIENCY; GALACTOSEMIA; GENE MUTATION; GLYCOGEN STORAGE DISEASE TYPE 1; HEMATOCRIT; HOMOCYSTINURIA; HUMAN; INFORMED CONSENT; MAPLE SYRUP URINE DISEASE; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE DEFICIENCY; NEWBORN; NEWBORN SCREENING; NOTE; PHENYLKETONURIA; SENSITIVITY AND SPECIFICITY; SICKLE CELL ANEMIA; TANDEM MASS SPECTROMETRY;

EID: 38349053112     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020701813743     Document Type: Article

References (74)

1. Folling A. Uber Ausscheidung von Phenylbrenztraubensaur in den Harn als Stoffwechselanomalie in Verbindung mit Imbezillitat. Z Physiol Chem 1934; 227: 169 .
2. Woolf LI, Griffiths R, Moncrieff A. Treatment of phenylketonuria with a diet low in phenylalanine. Br Med J 1955; 1: 57-64.
3. Bickel H, Gerrard J, Hickmans EM. Influence of phenylalanine intake on phenyketonuria. Lancet 1953; 265: 812-3.
4. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963; 32: 338-43.
5. MacCready RA, Hussey MG. Newborn phenylketonuria detection program in Massachusetts. Am J Public Health Nations Health 1964; 54: 2075-81.
6. Popkins JS, Clow CL, Scriver CR, Grove J. Is hereditary histidinaemia harmful? Lancet 1974; 1: 721-2.
7. Dussault JH, Coulombe P, Laberge C, Letarte J, Guyda H, Khoury K. Preliminary report on a mass screening program for neonatal hypothyroidism. J Pediatr 1975; 86: 670-4.
8. Illig R, Torresanti T, Sobradillo B. Early detection of neonatal hypothyroidism by serial TSH determination in dried blood. Six months experience with a reliable, efficient and inexpensive method. Helv Paediatr Acta 1977; 32: 289-97.
9. Pang S, Murphey W, Levine LS, et al. A pilot newborn screening for congenital adrenal hyperplasia in Alaska. J Clin Endocrinol Metab 1982; 55: 413-20.
10. Pang SY, Wallace MA, Hofman L, et al. Worldwide experience in newborn screening for classical congential adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988; 81: 866-74.
11. Crossley JR, Elliott RB, Smith PA. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet 1979; 1: 472-4.
12. Lees CM, Davies S, Dezateux C. Neonatal screening for sickle cell disease. Cochrane Database Syst Rev 2000; CD001913.
13. Wolf B, Heard GS. Biotinidase deficiency. Adv Pediatr 1991; 38: 1-21.
14. Beutler E. Galactosemia: screening and diagnosis. Clin Biochem 1991; 24: 293-300.
15. Millington DS, Kodo N, Norwood DL, Roe CR. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis 1990; 13: 321-4.
16. McCabe ER, Huang SZ, Seltzer WK, Law ML. DNA microextraction from dried blood spots on filter paper blotters: potential applications to newborn screening. Hum Genet 1987; 75: 213-6.
17. Bradley DM, Parsons EP, Clarke AJ. Experience with screening newborns for Duchenne muscular dystrophy in Wales. BMJ 1993; 306: 357-60.
18. Parsons EP, Bradley DM, Clarke AJ. Newborn screening for Duchenne muscular dystrophy. Arch Dis Child 2003; 88: 91-2.
19. Yokota T, Pistilli E, Duddy W, Nagaraju K. Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther 2007; 7: 831-42.
20. Aurino S, Nigro V. Readthrough strategies for stop codons in Duchenne muscular dystrophy. Acta Myol 2006; 25: 5-12.
21. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Geneva: World Health Organization, 1968.
22. ACMG Newborn Screening Expert Group. Newborn screening panel and system. Genet Med 2006; 8: 1-252S.
23. National Screening Committee. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. London: Health Department of the United Kingdom, 2003. www.library.nhs.uk/screening (accessed October 2007).
24. Scriver CR, Beaudet AL, Valle D, et al. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill, 2001.
25. Kaye CI, Accurso F, La FS, et al. Introduction to the newborn screening fact sheets. Pediatrics 2006; 118: 1304-12.
26. Koch R, Hanley W, Levy H, et al. Maternal phenylketonuria: an international study. Mol Genet Metab 2000; 71: 233-9.
27. Rose SR, Brown RS, Foley T, et al. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics 2006; 117: 2290-303.
28. Australasian Paediatric Endocrine Group. Guidelines for Management of Congenital Hypothyroidism. http://www.apeg.org.au/Portals/0/documents/ guidelines%20for%20management%20of%20congenital%20hypothyroidism.pdf (accessed October 2007).
29. Dubuis JM, Glorieux J, Richer F, Deal CL, Dussault JH, Van Vliet G. Outcome of severe congenital hypothyroidism: closing the developmental gap with early high dose levothyroxine treatment. J Clin Endocrinol Metab 1996; 81: 222-7.
30. Wilcken B, Gaskin K. More evidence to favour newborn screening for cystic fibrosis. Lancet 2007; 369: 1146-7.
31. Farrell PM, Kosorok MR, Laxova A, et al. Nutritional benefits of neonatal screening for cystic fibrosis. N Engl J Med 1997; 337: 963-9.
32. Waters DL, Wilcken B, Irwing L, et al. Clinical outcomes of newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 1999; 80: F1-7.
33. McKay KO, Waters DL, Gaskin KJ. The influence of newborn screening for cystic fibrosis on pulmonary outcomes in New South Wales, Australia. J Pediatr 2005; 147: S47-50.
34. Grosse S, Boyle CA, Cordero JF. Newborn screening for cystic fibrosis: recommendations from the Centers for Disease Control and Prevention. Am Fam Physician 2006; 71: 1482-7.
35. Wilcken B, Wiley V, Sherry G, Bayliss U. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. J Pediatr 1995; 127: 965-70.
36. Seltzer WK, Accuros F, Fall MZ, et al. Screening for cystic fibrosis: feasibility of molecular genetic analysis of dried blood specimens. Biochem Med Metab Biol 1991; 46: 105-9.
37. Wilcken B. Newborn screening for cystic fibrosis: techniques and strategies. J Inherit Metab Dis 2007.
38. Padoan R, Genoni S, Moretti E, Seia M, Giunta A, Corbetta C. Genetic and clinical features of false-negative infants in a neonatal screening programme for cystic fibrosis. Acta Paediatr 2002; 91: 82-7.
39. Bowling FG, Brown ARD. Development of a protocol for newborn screening for disorders of the galactose metabolic pathway. J Inherit Metab Dis 1986; 9: 99-104.
40. Gitzelmann R, Bosshard NU. Partial deficiency of galactose-1-phosphate uridyltransferase. Eur J Pediatr 1995; 154: S40-4.
41. Cutfield WS, Webster D. Newborn screening for congenital adrenal hyperplasia in New Zealand. J Pediatr 1995; 126: 118-21.
42. Rauh M, Groschl M, Rascher W, Dorr HG. Automated, fast and sensitive quantification of 17 alpha-hydroxy-progesterone, androstenedione and testosterone by tandem mass spectrometry with on-line extraction. Steroids 2006; 71: 450-8.
43. Lacey JM, Minutti CZ, Magera MJ, et al. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem 2004; 50: 621-5.
44. Rinaldo P, Tortorelli S, Matern D. Recent developments and new applications of tandem mass spectrometry in newborn screening. Curr Opin Pediatr 2004; 16: 427-33.
45. Chace DH, Kalas TA. A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. Clin Biochem 2005; 38: 296-309.
46. Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 2003; 49: 1797-817.
47. Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003; 348: 2304-12.
48. Zytkovicz TH, Fitzgerald EF, Marsden D, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem 2001; 47: 1945-55.
49. Wiley V, Carpenter K, Wilcken B. Newborn screening with tandem mass spectrometry: 12 months' experience in NSW Australia. Acta Paediatr Suppl 1999; 88: 48-51.
50. Frazier DM, Millington DS, McCandless SE, et al. The tandem mass spectrometry newborn screening experience in North Carolina: 1997-2005. J Inherit Metab Dis 2006; 29: 76-85.
51. Schulze A, Lindner M, Kohlmuller D, Olgemoller K, Mayatepek E, Hoffmann GF. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics 2003; 111: 1399-406.
52. Andresen BS, Dobrowolski SF, O'Reilly L, et al. Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 2001; 68: 1408-18.
53. Wilcken B, Haas M, Joy P, et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. Lancet 2007; 369: 37-42.
54. Nennstiel-Ratzel U, Arenz S, Maier EM, et al. Reduced incidence of severe metabolic crisis or death in children with medium chain acyl-CoA dehydrogenase deficiency homozygous for c.985A4G identified by neonatal screening. Mol Genet Metab 2005; 85: 157-9.
55. Lindner M, Ho S, Fang-Hoffmann, Hoffman GF. Neonatal screening for glutaric aciduria type 1: strategies to procede. J Inherit Metab Dis 2006; 29: 378-82.
56. Kolker S, Garbade SF, Boy N, et al. Decline of acute encephalopathic crises in children with glutaryl-CoA dehydrogenase deficiency identified by newborn screening in Germany. Pediatr Res 2007; 62: 1-7.
57. Simon E, Fingerhut R, Baumkotter J, Konstantopoulou V, Ratschmann R, Wendel U. Maple syrup urine disease: favourable effect of early diagnosis by newborn screening on the neonatal course of the disease. J Inherit Metab Dis 2006; 29: 532-7.
58. Bhattacharya K, Khalili V, Wiley V, Carpenter K, Wilcken B. Newborn screening may fail to identify intermediate forms of maple syrup urine disease. J Inherit Metab Dis 2006; 29: 586.
59. Liebig M, Schymik I, Mueller M, et al. Neonatal screening for very long chain acyl-CoA dehydrogenase deficiency: enzymatic and molecular evaluation of neonates with elevated C14:1-carnitine. Pediatrics 2006; 118: 1065-9.
60. van Maldegem BT, DuranM,Wanders RJ, et al. Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme A dehydrogenase deficiency. JAMA 2006; 296: 943-52.
61. Koeberl DD, Millington DS, Smith WE, et al. Evaluation of 3-methylcrotonyl-CoA carboxylase deficiency detected by tandem mass spectrometry newborn screening. J Inherit Metab Dis 2003; 26: 25-35.
62. Scriver CR, Levy HL. Histidinaemia. Part I: Reconciling retrospective and prospective findings. J Inherit Metab Dis 1983; 6: 51-3.
63. Haas M, Chaplin M, Joy P, Wiley V, Black C, Wilcken B. Healthcare use and costs of medium-chain acyl-CoA dehydrogenase deficiency in Australia: screening versus no screening. J Pediatr 2007; 151: 121-6.
64. Gilbert R, Dezateux C. Newborn screening for congenital toxoplasmosis: feasible, but benefits are not established. Arch Dis Child 2006; 91: 629-31.
65. Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005; 352: 2069-81.
66. Li Y, Brockmann K, Turecek F, Scott CR, Gelb MH. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for Krabbe disease. Clin Chem 2004; 50: 638-40.
67. Pass KA, Green NS, Lorey F, Sherwin JE, Comeau AM. Pilot programs in Newborn Screening. Ment Retard Dev Disabil Res Rev 2006; 12: 293-300.
68. Meikle PJ, Grasby DJ, Dean CJ, et al. Newborn screening for lysosomal storage disorders. Mol Genet Metab 2006; 88: 307-14.
69. Gelb MH, Turecek F, Scott CR, Chamoles NA. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis 2006; 29: 397-404.
70. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447: 87-91.
71. Singh LR, Chen X, Kozich V, Kruger WD. Chemical chaperone rescue of mutant human cystathionine beta-synthase. Mol Genet Metab 2007; 91: 335-42.
72. Dantonio P, Meredith N, Earley M, et al. A screening system for detecting genetic risk markers of type 1 diabetes in dried blood spots. Diabetes Technol Ther 2006; 8: 433-43.
73. Lorini R, Minicucci L, Napoli F, et al. Screening for type 1 diabetes genetic risk in newborns of continental Italy. Acta Biomed 2005; 76: 31-5.
74. Hiraki S, Ormond KE, KimK, Ross LF. Attitudes of genetic counselors towards expanding newborn screening and offering predictive genetic testing to children. Am J Med Genet 2006; 140: 2312-9.